Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

Clinical and Experimental Immunology

Volumn 110, Issue 2, 1997, Pages 158-166

  Isaacs, J D ^a,d   Burrows, N ^b   Wing, M ^c   Keogan, M T ^b   Rebello, P R U B ^a   Watts, R A ^b   Pye, R J ^b   Norris, P ^b   Hazelman, B L ^b   Hale, G ^a   Waldmann, H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anti CD4; CAMPATH; Immunotherapy; Psoriasis; Rheumatoid arthritis

Indexed keywords

CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; DRUG EFFECT; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 9844258325     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.tb08312.x     Document Type: Article

References (52)

1. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986; 320:449-51.
2. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody therapy to L3T4. J Immunol 1986; 137:1127-32.
3. Qin S, Cobbold S, Benjamin R, Waldmann H. Induction of classical transplantation tolerance in the adult. J Exp Med 1989; 169:779-94.
4. Cobbold SP, Qin S, Leong LYW, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CDS monoclonal antibodies. Immunol Rev 1992; 129:165-201.
5. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H. 'Infectious' transplantation tolerance. Science 1993; 259:974-7.
6. Herzog C, Walker C, Muller W et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun 1989; 2:627-42.
7. Reiter C, Kakarand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal anti-CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991; 34:525-36.
8. Goldberg D, Morel P, Chatenoud L, Boitard C, Menkes C-J, Bertoye PH, Revillard J-P, Bach J-F. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 1991; 4:617-30.
9. Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34:129-40.
10. Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991; 18:325-7.
11. Moreland LW, Bucy RP, Tilden A et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36:307-18.
12. Morel P, Revillard J-P, Nicolas J-F, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992; 5:465-77.
13. Hiepe F, Volk H-D, Apostoloff E, Baehr RV, Emmrich F. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 1991; 338:1529-30.
14. Racadot E, Rumbach L, Bataillard M et al. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on BF-5 in 21 patients. J Autoimmun 1993; 6:771-86.
15. Lindsey JW, Hodgkinson S, Mehta R et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994; 44:413-19.
16. Moreland LW, Pratt PW, Mayes MD et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412 in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum 1995; 38:1581-8.
17. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38:1097-106.
18. Levy R, Weisman M, Weizenhutter C et al. Results of a placebo-controlled, multicenter trial using a primatized, non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996; 39:S122.
19. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341:1620-2.
20. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q J Med 1996; 89:903-12.
21. German SD, Clark MR, Routledge EG, Cobbold SP, Waldmann H. Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci USA 1991; 88:4181-5.
22. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7.
23. Baker BS, Swain AF, Valdimarsson H, Fry L. T cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 1984; 110:37.
24. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981; ii:839-42.
25. Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliveira DBG, Lockwood CM, Waldmann H. Monoclonal antibody therapy in systemic vasculitis. New Engl J Med 1990; 323:250-4.
26. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340:748-52.
27. Frederickson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
28. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association revized criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
29. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 147:393-406.
30. Isaacs JD, Wing M, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 1996; 106:427-33.
31. Cobbold SP, Rebello PRUB, Davies HFFS, Friend PJ, Clark MR. A simple method for measuring patient antiglobulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990; 127:19-24.
32. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-61.
33. Bruggemann MC, Teale C, Clark MR, Bindon C, Waldmann H. A matched set of rat/mouse chimeric antibodies: identification and biological properties of rat H chain constant regions μ., γ1, γ2a, γ2b, γ2c, ∈ and α. J Immunol 1989; 142:3145-50.
34. Bindon CI, Hale G, Waldinann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18:1507-14.
35. Bindon CI, Hale G, Waldmann H. Complement activation by immunoglobulin does not depend solely on C1q binding. Eur J Immunol 1990; 20:277-81.
36. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168:127-42.
37. + T cell counts. Arthritis Rheum 1994; 37:834-8.
38. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992; 148:3062-71.
39. van der Lubbe PA, Reiter C, Breedveld FC, Kruker K, Schattenkirchner M, Sanders ME, Reithmuller G. Chimeric CD4 monoclonal antibody CM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993; 36:1375-9.
40. Isaacs JD, Waldmann H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic antibodies. Ther Immunol 1994; 1:303-12.
41. Benjamin RJ, Cobbold SP, Clark MR, Waldinann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 1986; 163:1539-52.
42. + cells. J Immunol 1986; 137:3414-19.
43. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119:225-37.
44. Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49:697-702.
45. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldinann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-11.
46. Wing MG, Isaacs JD, Waldinann H, Compston DAS, Hale G. Exvivo blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther Immunol 1999; 2:183-90.
47. Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis - an iv dose-ranging study. Br J Rheumatol 1996; 35:231-40.
48. Waldmann H, Cobbold SP. How may immunosuppression lead to tolerance? The war analogy. In: Plotkin S, Fantini B, eds. Immune tolerance: Jenner, Pasteur and their successors. Paris: Elsevier, 1997.
49. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991-1045.
50. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas. leukaemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31:691-6.
51. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35:738-45.
52. Choy EHS, Connolly DJA, Regan T, Manna VK, Rapson N, Kingsley GH, Panayi GS, Johnston JM. T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment II: Clinical activity is related to pharmacodynamic effects. Arthritis Rheum 1996; 39:S244.